Robinhood Asset Management LLC Makes New Investment in Natera, Inc. $NTRA

Robinhood Asset Management LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 41,175 shares of the medical research company’s stock, valued at approximately $11,177,000.

Other hedge funds have also recently modified their holdings of the company. Trust Co. of Vermont acquired a new stake in shares of Natera in the 2nd quarter valued at about $26,000. Elevation Wealth Partners LLC acquired a new position in Natera during the second quarter worth approximately $30,000. Reflection Asset Management acquired a new position in Natera during the fourth quarter worth approximately $29,000. Palladiem LLC purchased a new stake in Natera in the fourth quarter valued at approximately $31,000. Finally, Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Barclays restated an “overweight” rating and set a $340.00 target price on shares of Natera in a research report on Friday, August 7th. The Goldman Sachs Group assumed coverage on shares of Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target for the company. Leerink Partners set a $330.00 price target on shares of Natera in a research note on Friday, August 7th. Evercore reissued an “outperform” rating and set a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $355.00 target price on shares of Natera in a report on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 3,076 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares of the company’s stock, valued at $26,611,561.83. This represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares of the company’s stock, valued at $34,264,866.02. The trade was a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 181,045 shares of company stock valued at $41,330,968 in the last three months. 5.05% of the stock is owned by corporate insiders.

Natera Stock Up 2.2%

NASDAQ NTRA opened at $332.03 on Friday. The stock has a market capitalization of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $333.56. The firm has a 50-day moving average price of $274.24 and a 200 day moving average price of $229.39.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The firm’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.74) EPS. On average, equities research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.